Literature DB >> 31361525

Lung Cancer Recurrence: 18F-FDG PET/CT in Clinical Practice.

Asha Kandathil1, Robert Carson Sibley1, Rathan M Subramaniam1.   

Abstract

OBJECTIVE: The purpose of this article is to summarize the clinical utility of 18F-FDG PET/CT in the evaluation of lung cancer recurrence with an emphasis on typical anatomic and metabolic patterns of recurrence, expected posttherapeutic changes, and common pitfalls of FDG PET/CT. FDG PET/CT is useful in assessing therapeutic response and in determining the extent of recurrent disease and provides a guide for targeted biopsy.
CONCLUSION: FDG PET/CT plays a crucial role in the evaluation of therapeutic response in lung cancer and guides management.

Entities:  

Keywords:  18F-FDG PET/CT; lung cancer recurrence; response assessment

Year:  2019        PMID： 31361525     DOI： 10.2214/AJR.19.21227

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  7 in total

1.  Post-treatment lung cancer patients: residual tumor, recurrence, and second primary tumor.

Authors:  Dante Luiz Escuissato; Danny Warszawiak
Journal:  J Bras Pneumol       Date:  2021-09-06       Impact factor: 2.624

2.  Associated factors with constipation and health-related quality of life in lung cancer patients with platinum-based chemotherapy: A cross-sectional study.

Authors:  Huamao Chen; Xixi Gu; Yan Zhang; Jian Feng; Yan Gu
Journal:  Medicine (Baltimore)       Date:  2021-07-30       Impact factor: 1.817

3.  Evaluation of an Automatic Classification Algorithm Using Convolutional Neural Networks in Oncological Positron Emission Tomography.

Authors:  Pierre Pinochet; Florian Eude; Stéphanie Becker; Vijay Shah; Ludovic Sibille; Mathieu Nessim Toledano; Romain Modzelewski; Pierre Vera; Pierre Decazes
Journal:  Front Med (Lausanne)       Date:  2021-02-26

4.  Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by 18F-FDG PET/CT Radiomics and Clinicopathological Characteristics.

Authors:  Jihui Li; Shushan Ge; Shibiao Sang; Chunhong Hu; Shengming Deng
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 5.  Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.

Authors:  Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-13       Impact factor: 10.057

Review 6.  Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer.

Authors:  Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei
Journal:  Radiother Oncol       Date:  2022-01-20       Impact factor: 6.901

7.  Influencing Factors and Prognostic Value of 18F-FDG PET/CT Metabolic and Volumetric Parameters in Non-Small Cell Lung Cancer.

Authors:  Lixia Zhang; Zhe Ren; Caiyun Xu; Qiushuang Li; Jinyan Chen
Journal:  Int J Gen Med       Date:  2021-07-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.